As part of the plan, Amazon has agreed to purchase 100,000 electric delivery vans from vehicle manufacturer Rivian.Technologyread more
The plan will allow Medicare to negotiate lower prices on as many as 250 drugs and also apply those discounts to private health plans.Health and Scienceread more
The U.S. economy will have a tough time at the start of 2020, says the head of one of the largest bond managers in the world.Delivering Alpharead more
President Donald Trump on Thursday filed a lawsuit against Manhattan District Attorney Cyrus Vance Jr. and his longtime accounting firm Mazars.Politicsread more
The Democratic-held House plans to move forward with a bill to fund the government through Nov. 21 and avoid another government shutdown.Politicsread more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
A new Hollister store is coming later this month to New York, right down the block from Macy's, Target and Victoria's Secret in the busy Herald Square shopping district.Retailread more
Newly public ride-sharing companies Uber and Lyft have tumbled 25% since their initial public offerings, but Light Street's Glen Kacher still believes there's a path for...Delivering Alpharead more
The Federal Reserve has calmed the overnight funding market and brought its fed funds rate back in line with its target.Market Insiderread more
The PSA features kids in what initially appears to be a cheerful spot. But it becomes darker as children show how their "back to school" products help in the context of a...Politicsread more
The formats will be available for Facebook's News Feed.Technologyread more
Short-seller Andrew Left said Friday that it was "completely outrageous" for the Senate to try to make Mylan "the next victim of public outcry over pharmaceutical pricing."
The founder of Citron Research explained that Mylan became "a great whipping boy" for the Senate because the EpiPen is a consumer brand with name recognition. Mylan is a "well-diversified company" and the Senate "picked on the wrong company," Left argued.
"I understand that things have changed since Valeant. I understand that it will never be the way it used to be, but Mylan has been completely collateral damage to the real culprits in this business," Left said.
Sen. Claire McCaskill, D-Mo., the ranking member of the Senate's Special Committee on Aging, should be looking at Mallinckrodt, which Left called a "true abuser of the system."
Mallinckrodt did not immediately respond to CNBC's request for comment.
Left has been outspoken about his short position or bet against Mallinckrodt.
In March, Left said on "Fast Money" that Mallinckrodt makes Valeant look like a "choirboy" in comparison and that Mallinckrodt's drug Acthar, used to treat seizures in babies, is the "poster child" of price gouging.
Mallinckrodt CEO Mark Trudeau defended the company and said it is "absolutely not Valeant."
"First and foremost, Mallinckrodt is a well-diversified, strong company. We're transparent. Our strength is both operational and financial," Trudeau said on "Fast Money" in March.
— CNBC's Pippa Stevens contributed to this report.